Introduction {#S1}
============

The increase in antibiotic resistant strains is a global public health concern in the continuous fight against pathogens. Owing to the lack of efficient drugs, it is estimated that 400,000 infections and more than 25,000 deaths occur annually in the European Union alone ([@B22]; [@B10]), creating also a significant economic impact of over €1.5 billion ([@B60]; [@B53]). As alternatives to antibiotics, many researchers have explored the use of essential oils (EOs) or other bioactive compounds occurring naturally as secondary metabolites of aromatic and medicinal plants ([@B33]; [@B42]; [@B6]; [@B4]; [@B26]; [@B56]). EOs are oily liquids rich in aromatic compounds, which are extracted from plant material mainly by steam- or hydrodistillation ([@B5]). Owing to their antiseptic, antibacterial, antifungal, anti-inflammatory, antinociceptive, anticancer, antioxidant, and analgesic properties ([@B3]), they have a long history of use in traditional medicine ([@B54]), cosmetology ([@B2]), crop protection ([@B17]), and also in food preparation and preservation ([@B9]). The mechanism of antibacterial action of EOs is attributed either or collectively to the disruption of the bacterial cytoplasmic membrane and various diverse effects upon cellular metabolism ([@B42]; [@B71]; [@B18]).

However, despite their traditional use and proven biological properties, the use of EOs as antibacterial agents is constrained from limitations or disadvantages in their efficiency, variation in composition, toxicity, usability, bacterial resistance, and lack of knowledge of their mode of action ([@B6]; [@B7]; [@B51]). In this context, as an alternative strategy, the combined action of existing antibiotics with complex phytochemicals or with their individual components was suggested from various investigators ([@B34]; [@B73]; [@B38]; [@B44]; [@B46]; [@B51]). This strategy combines the multidrug resistant modifier action of phytochemicals with the selectivity of antibiotics to overcome the intrinsic or acquired resistance mechanisms of bacteria with promising results toward their efficacy and commercialization viability ([@B34]; [@B51]).

In 2001, [@B37] successfully inhibited β-lactamase in β-lactamase-producing *Staphylococcus aureus* combining epigallocatechin-gallate and ampicillin/sulbactam, while [@B55] inhibited methicillin-resistant *S. aureus* and vancomycin enterococci via the combination of α-mangostin with vancomycin. Since then, various studies have proven the successfulness of such combinations, with some of them demonstrating a remarkable up to 256-fold reduction in the antibiotic concentration ([@B51]). Similar results from the combined use of phytochemicals have also been obtained in various food models as well ([@B36]).

Of the well-known aromatic and medicinal plants, mints of the *Lamiaceae* family include more than 20 species and natural hybrids. Their properties were discovered in ancient times, and today, several mint species and their EOs are exploited at various fields in medicine ([@B52]; [@B41]; [@B7]). Their properties are related to the volatile compounds that constitute their EO, of which pulegone, carvone, and menthol have been extensively studied ([@B59]; [@B64], [@B65]; [@B70]).

Piperitenone and its epoxide (PEO) and peroxide (PPO) derivatives are among the not so well-studied components occurring in EOs of various plants. These p-menthane type monoterpenes are natural constituents of the chemotypes of various plant species as *Calamintha nepeta* and *Calamintha glandulosa* ([@B40]; [@B16]), *Satureja parvifolia* ([@B75]), *Hyptis capitata* ([@B67]), *Tagetes patula* ([@B63]), *Rosmarinus officinalis* ([@B28]), *Eucalyptus olida*, *Eucalyptus dives* ([@B30]), and *Micromeria congesta* ([@B35]). However, it is in the *Lamiaceae* family and particularly in mint genus where PPO and PEO are among the main monoterpene components. Geographical origin, cultivation techniques, and even isolation methods are among the factors that influence plants' EOs composition ([@B13]; [@B66]) resulting most often in PPO and PEO being isolated from various *Mentha* spp. as minor ingredients and in percentages close to 1% ([@B21]; [@B61]). In other mint species, however, these compounds are abundant and consisting a high percentage (from 40 to 85.4%) of their volatiles ([@B68]; [@B23]; [@B28]; [@B8]). *Mentha* spp. rich in PPO/PEO have been reported from China ([@B74]), Israel ([@B57]), Jordan ([@B1]), Lithuania ([@B72]), and Greece ([@B40]).

Epoxides, in general, are active compounds, and various studies have shown that, in mammals, they are able to react with nucleophilic groups in proteins ([@B31]) or acting as haptens, eliciting significant reactions to the skin ([@B49]). [@B62] reported an antinociceptive activity of PPO in mice and suggest that this effect is probably an indirect anti-inflammatory reaction.

Despite the fact that there are numerous reports concerning the antimicrobial activities of EOs against pathogens ([@B43]), there are relatively limited studies exploiting the combined action of EOs and antibiotics ([@B44]; [@B51]). Among them, there is not, to our knowledge, a similar study concerning the combined action of PEO and antibiotics against clinical pathogens. Therefore, the aim of the present work was to assess the antimicrobial efficiency of PEO in combination with various antibiotics against *S. aureus* and *Escherichia coli* strains isolated from clinical samples.

Materials and Methods {#S2}
=====================

Bacterial Strains {#S2.SS1}
-----------------

Twenty-eight clinical strains of *S. aureus* and 10 clinical strains of *E. coli* were used in the study. These strains were donated over time from "Metaxa" Anticancer Hospital and are now part of the frozen strain collection of the Laboratory of Microbiology, Biotechnology and Hygiene. Strains have been identified via VITEK 2 Compact (BioMerieux, Marcy-l'Étoile, France) and kept frozen in Tryptone Soya Broth (HiMedia Laboratories Pvt. Ltd., Mumbai, India) enriched with 30% glycerol until use. *S. aureus* strains were non-methicillin-resistant, and *E. coli* were non-extended spectrum β-lactamase producers as revealed by latex agglutination test (Oxoid^TM^ Ltd., United Kingdom) and Clinical and Laboratory Standard Institute (CLSI) double disk method ([@B32]). *Staphylococcus aureus* ATCC^®^ 25923^TM^ and *E. coli* ATCC^®^ 25922^TM^ were used as reference strains. Before assays, all strains were incubated in the appropriate conditions to ensure optimal growth and purity. In the present study, no human or animal subjects were involved or any recorded data are used or maintained, and therefore, no ethics approval is required.

Isolation and Characterization of Piperitenone Epoxide {#S2.SS2}
------------------------------------------------------

Isolation and structural characterization of PEO followed the procedure as we previously described ([@B39]). Briefly, aerial parts of full flowered plants of *M. spicata* were collected during July of 2018 from a wild-growing population in Sparti (South of Greece, Peloponisos). Plant material was air dried and cut into small pieces, and 500 g was subjected to hydrodistillation for 3 h, using a Clevenger type apparatus. The collected EO (1.8 ml/100 g dry wt) was dried over anhydrous magnesium sulfate, filtrated, and finally stored in sterile screw capped dark bottles at −22°C until use. Gas chromatographic--mass spectroscopic analysis (GC-MS) revealed, as expected, piperitone epoxide (23.2%) and PEO (50.9%) as the major ingredients. Part of the extracted crude EO (4 g) was fractioned by column chromatography on silica gel and eluted with a gradient of solvents of increasing polarity (pentane+diethyl). The resulted yellowish oil, identified as (+)-PEO (1.6 g, mixture of *cis* and *trans* diastereoisomers), was found in high purity (∼99.0%) according to GC-MS analysis. Structural determination was carried out by GC-MS and ^1^H- and ^13^C-NMR analysis, and the results were in agreement to previously reported ([@B39]).

Determination of Minimum Inhibitory Concentration {#S2.SS3}
-------------------------------------------------

The minimum inhibitory concentration (MIC) of the various antibiotics was determined using commercially available 96-well microplate panels (Sensititre^®^, Trek Diagnostic System), preloaded with antibiotics ([Table 1](#T1){ref-type="table"}) following the method recommended by [@B14]. Assays were performed in Muller--Hinton broth (MHB) (HiMedia Laboratories Pvt. Ltd., Mumbai, India). In each well, 100 μl of MHB was added along with 20 μl of a diluted bacterial suspension in NaCl 0.85% to give a final concentration of 5 × 10^5^ CFU/ml. Wells without bacteria were used as negative controls. Plates were incubated for 16--24 h at 37°C, and growth was assessed after addition of tetrazolium dye \[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide or MTT\] (Sigma-Ardrich^®^) and further incubated for 60 min. The MIC was defined as the lowest antibiotic concentration without visible growth. Three independent assays were performed.

###### 

Concentrations of antibiotics used for *Staphylococcus aureus* and *Escherichia coli* in the assay.

  **Antibiotic**   ***S. aureus* (test range in μg/ml)**   **Dilutions^∗^**   ***E. coli* (test range in μg/ml)**   **Dilutions^∗^**
  ---------------- --------------------------------------- ------------------ ------------------------------------- ------------------
  Amikacin         nt                                      --                 64--0.5                               7
  Ampicillin       16--0.06                                8                  32--0.5                               6
  Cefepime         nt                                      --                 32--0.5                               6
  Ceftazidime      nt                                      --                 32--8                                 2
  Ceftriaxone      64--0.03                                11                 64--0.06                              10
  Levofloxacin     32--0.06                                9                  8--0.008                              10
  Linezolid        8--0.5                                  4                  nt                                    --
  Meropenem        16--0.12                                7                  16--0.06                              8
  Minocycline      8--0.25                                 6                  16--0.5                               5
  Penicillin       8--0.06                                 7                  nt                                    --
  Tigecycline      16--0.008                               11                 16--0.008                             11
  Vancomycin       32--0.12                                8                  nt                                    --

∗

Number of twofold dilutions starting from the largest concentration, nt, not tested.

The MIC of PEO against pathogens was determined also by the broth microdilution method. A bacterial suspension was prepared in MHB from fresh overnight stock culture bearing a final concentration of 1.5 × 10^8^ CFU/ml or 0.5 McFarland turbidity units estimated using a dedicated densitometer (DensiCHEK^TM^ Plus, Biomerieux). In each well, 100 μl of MHB was added supplemented with dimethyl sulfoxide at a final concentration of 2% (*v*/*v*) to ensure oil solubility. In the first column of wells, 50 μl of PEO was added (1,024 μg/ml) and serially diluted horizontally to a final concentration of 0.25 μg/ml. An aliquot of 50 μl from bacterial suspension was added to each well. Plates were covered and incubated at 37°C for 16--24 h. The MIC was defined as the lowest concentration with no visible growth.

Checkerboard Assay {#S2.SS4}
------------------

To study the combined action of antibiotics and PEO, five Sensititre^®^ plates were used for every strain with each one of the plates containing a different concentration of PEO. The concentrations of PEO used were selected on the basis of MIC values previously determined (four twofold dilutions starting at 32 mg/l (i.e., 32, 16, 8, and 4 μg/ml). Higher concentrations of PEO could be effective also but unworthy for clinical exploitation. MHB used in combined experiments was supplemented with dimethyl sulfoxide (Sigma-Ardrich^®^) at a final concentration of 2% (*v*/*v*). Incubation conditions and interpretation of results were similar to the ones already described. The combined action of the antibiotics and PEO was expressed in terms of fractional inhibitory concentration (FIC) index (FICI) equal to the sum of FICs for each drug. The FIC is defined as the MIC of each substance or drug used in combination divided by the MIC of the substance or drug used alone based on the following equation ([@B20]):
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The results were considered as a synergistic effect if the FICI of the combination is ≤0.5, additive when 0.5 \< FICI \< 1, indifferent when 1 \< FICI ≤ 2, and antagonistic for FICI \> 2 ([@B24]). All experiments were performed in triplicate.

Statistical Analysis {#S2.SS5}
--------------------

Comparison of the mean MIC values of PEO and antibiotics against *S. aureus* and *E. coli* was performed with the Mann--Whitney non-parametric procedure at an alpha level of 0.05.

Results {#S3}
=======

Minimum Inhibitory Concentration of PEO and Antibiotics {#S3.SS1}
-------------------------------------------------------

In our study, overall MIC values of PEO ranged between 32 and 1,024 μg/ml ([Table 2](#T2){ref-type="table"}). The average MIC (μg/ml) of PEO against the 10 *E. coli* strains was 512.2 ± 364.7 μg/ml, which is significantly higher (Mann--Whitney *p* \< 0.05) than 172.8 ± 180.7 μg/ml observed for the 28 *S. aureus* strains.

###### 

Minimum inhibitory concentrations (μg/ml) of piperitenone epoxide (PEO) and antibiotics against clinical isolates of *Escherichia coli* and *Staphylococcus aureus*.

  **Minimum inhibitory concentration (μg/ml)^∗^**                                                                                    
  ------------------------------------------------- ------ ---- ------ ------- ----- ------ ------ ----- ------ ------ ------ ------ ------
  *E. coli 1*                                       256    4    32     16      16    2      0.06   nt    2      2      nt     0.5    nt
  *E. coli 2*                                       512    4    32     4       32    4      0.12   nt    1      4      nt     0.5    nt
  *E. coli 3*                                       1024   1    8      4       32    4      2      nt    2      16     nt     0.25   nt
  *E. coli 4*                                       512    4    32     16      32    8      0.06   nt    2      2      nt     0.25   nt
  *E. coli 5*                                       512    4    32     32      16    64     2      nt    4      16     nt     0.12   nt
  *E. coli 6*                                       128    4    32     2       32    32     8      nt    2      16     nt     0.12   nt
  *E. coli 7*                                       128    4    32     8       16    64     8      nt    4      16     nt     0.12   nt
  *E. coli 8*                                       512    4    32     16      32    8      0.06   nt    2      2      nt     0.25   nt
  *E. coli 9*                                       1024   1    8      4       32    4      2      nt    2      16     nt     0.25   nt
  *E. coli 10*                                      512    4    8      2       32    8      0.06   nt    2      2      nt     0.25   nt
  *E. coli 25922*                                   512    1    4      \<0.5   \<8   0.05   0.06   nt    0.06   2      nt     0.25   nt
  *S. aureus 1*                                     256    nt   32     nt      nt    8      0.5    4     0.5    0.25   0.5    0.12   2
  *S. aureus 2*                                     64     nt   32     nt      nt    16     0.5    16    2      2      1      0.12   2
  *S. aureus 3*                                     128    nt   0.25   nt      nt    4      0.5    8     0.25   1      0.25   0.06   1
  *S. aureus 4*                                     128    nt   2      nt      nt    4      0.25   8     0.5    0.5    0.25   0.25   1
  *S. aureus 5*                                     64     nt   32     nt      nt    16     32     2     1      0.25   0.5    0.06   1
  *S. aureus 6*                                     128    nt   16     nt      nt    8      4      8     0.25   0.25   0.5    0.12   1
  *S. aureus 7*                                     128    nt   16     nt      nt    16     0.25   4     0.12   0.25   0.25   0.06   1
  *S. aureus 8*                                     256    nt   0.12   nt      nt    4      0.5    4     0.5    0.5    0.06   0.12   2
  *S. aureus 9*                                     128    nt   16     nt      nt    8      0.25   8     0.5    0.5    0.5    0.12   1
  *S. aureus 10*                                    64     nt   16     nt      nt    4      1      4     0.5    0.5    0.5    0.25   1
  *S. aureus 11*                                    256    nt   16     nt      nt    16     8      8     2      1      1      0.12   1
  *S. aureus 12*                                    128    nt   16     nt      nt    8      0.5    8     0.25   1      0.5    0.12   2
  *S. aureus 13*                                    128    nt   16     nt      nt    8      1      8     0.5    1      1      0.12   2
  *S. aureus 14*                                    64     nt   16     nt      nt    4      0.5    8     0.25   0.5    0.06   0.12   1
  *S. aureus 15*                                    256    nt   16     nt      nt    8      1      4     0.25   0.5    0.12   0.12   1
  *S. aureus 16*                                    256    nt   16     nt      nt    4      0.5    8     0.12   1      0.5    0.25   1
  *S. aureus 17*                                    256    nt   16     nt      nt    4      1      8     0.25   1      0.5    0.06   1
  *S. aureus 18*                                    32     nt   16     nt      nt    16     2      8     0.25   8      0.06   0.25   1
  *S. aureus 19*                                    256    nt   16     nt      nt    8      2      8     0.25   1      0.12   0.12   1
  *S. aureus 20*                                    64     nt   16     nt      nt    8      1      8     0.5    2      0.5    0.25   1
  *S. aureus 21*                                    32     nt   16     nt      nt    8      0.5    8     0.25   8      0.5    0.12   1
  *S. aureus 22*                                    128    nt   16     nt      nt    16     4      8     0.25   8      0.5    0.25   2
  *S. aureus 23*                                    32     nt   0.25   nt      nt    4      0.5    8     0.25   1      0.25   0.06   4
  *S. aureus 24*                                    32     nt   16     nt      nt    8      0.5    8     0.25   1      0.12   0.12   2
  *S. aureus 25*                                    1024   nt   16     nt      nt    16     0.12   4     0.12   0.25   0.12   0.06   2
  *S. aureus 26*                                    256    nt   0.12   nt      nt    4      0.5    16    0.25   0.5    0.06   0.12   2
  *S. aureus 27*                                    128    nt   16     nt      nt    8      1      4     0.25   0.5    0.5    0.12   1
  *S. aureus 28*                                    128    nt   16     nt      nt    4      1      8     0.25   0.5    0.12   0.25   1
  *S. aureus 25923*                                 64     nt   0.25   nt      nt    4      0.06   0.5   0.12   0.25   0.12   0.06   0.25

∗

Mean values of three replicates, nt, not tested. Piperitenone epoxide (PEO), Amikacin (AMK), Ampicillin (AMP), Cefepime (FEP), Ceftazidime (CAZ), Ceftriaxone (CRO), Levofloxacin (LVX), Linezolid (LZD), Meropenem (MEM), Minocycline (MIN), Penicillin (PEN), Tigecycline (TGC), Vancomycin (VAN).

Based on the ecological cutoff values presented by [@B25], *E. coli* strains were proven to be multiresistant in almost all antibiotics. All 10 strains were resistant to cefepime (FEP), ceftazidime (CAZ), ceftriaxone (CRO), and meropenem (MEM) and sensitive to amikacin (AMK) and tigecycline (TGC). The resistance percentage of *E. coli* isolates to the rest of antibiotics ranged from 50 to 70%.

Similarly, an increased resistance to several antibiotics was observed for *S. aureus* isolates particularly in ampicillin (82.1%), linezolid (71.4%), and minocycline (82.1%). Resistance ranged from 10 to 25% for the rest of the antibiotics, while none of the *S. aureus* isolates was resistant to tigecycline and only one to vancomycin (3.6%). Resistance to penicillin (\>1 μg/ml) was recorded in three strains. *E. coli* and *S. aureus* reference strains were constantly exhibiting sensitivity to the majority of the drugs.

Fractional Inhibitory Concentration of PEO and Antibiotics {#S3.SS2}
----------------------------------------------------------

In our results, out of the 90 assays (240 with the replications) to determine the FICs from the combination of antibiotics and PEO on clinical isolates of *E. coli*, synergy, according to [@B24], was detected in 73 or 81.1% ([Table 3](#T3){ref-type="table"}). A complete synergistic effect was recorded in the case of amikacin/PEO, ampicillin/PEO, ceftazidime/PEO, meropenem/PEO, and minocycline/PEO, whereas 50--80% synergism was observed for the rest of the antibiotics when combined with PEO. Additive effects were exhibited by 10% of the FICIs and indifferent by 5.5%. No antagonistic interactions were recorded during the *E. coli* experiments ([Figure 1](#F1){ref-type="fig"}).

###### 

Mean values and interpretations according to EUCAST (2000) of fractional inhibitory concentration indexes (FICI) for piperitenone epoxide (PEO) and antibiotics against 10 *Escherichia coli* strains.

  **Strain**            **AMK**   **AMP**   **FEP**   **CAZ**   **CRO**   **LVX**   **MEM**   **MIN**   **TGC**
  --------------------- --------- --------- --------- --------- --------- --------- --------- --------- ---------
  *E. coli 1*           0.50      0.50      0.50      0.50      0.63      1.50      0.38      0.38      0.49
  *E. coli 2*           0.38      0.50      0.31      0.50      0.31      0.56      0.37      0.19      0.49
  *E. coli 3*           1.50      0.16      0.38      0.19      0.50      0.16      0.19      0.38      1.06
  *E. coli 4*           0.50      0.38      0.38      0.31      0.19      1.06      0.38      0.38      0.30
  *E. coli 5*           0.75      0.50      0.38      0.50      0.13      0.28      0.13      0.50      0.56
  *E. coli 6*           0.50      0.38      0.75      0.38      0.50      0.50      0.38      0.50      1.50
  *E. coli 7*           1.50      0.31      0.50      0.50      0.56      0.26      0.31      0.50      0.75
  *E. coli 8*           0.50      0.31      0.31      0.31      0.38      0.13      0.25      0.50      0.37
  *E. coli 9*           1.13      0.38      0.31      0.31      0.50      0.53      0.25      0.38      0.30
  *E. coli 10*          0.50      0.19      0.56      0.38      0.38      1.06      0.31      0.19      0.30
  *E. coli 25922*       0.50      0.16      0.31      0.19      0.19      0.19      0.31      0.19      0.37
  ^∗^Synergy (%)        60        100       80        100       80        50        100       100       60
  ^∗^Additive (%)       10        0         20        0         20        20        0         0         20
  ^∗^Indifference (%)   30        0         0         0         0         30        0         0         20
  ^∗^Antagonism (%)     0         0         0         0         0         0         0         0         0

∗

Reference strain not included. Amikacin (AMK), Ampicillin (AMP), Cefepime (FEP), Ceftazidime (CAZ), Ceftriaxone (CRO), Levofloxacin (LVX), Meropenem (MEM), Minocycline (MIN), Tigecycline (TGC).

![Chemical structure of piperitenone epoxide (PEO).](fmicb-10-02607-g001){#F1}

Among the *S. aureus* assays ([Table 4](#T4){ref-type="table"}), synergism was observed for all antibiotics but in variable percentages. Specifically, 67.86% of the ceftriaxone/PEO, levofloxacin/PEO, and linezolid/PEO combinations exhibited synergism (FICI ≤ 0.5). Similarly, synergism was observed in 60.71% of the vancomycin/PEO combination, 57.14% of ampicillin/PEO, 53.57% of penicillin/PEO, 42.86% minocycline/PEO, 35.71% of meropenem/PEO, and finally 3.57% of tigecycline/PEO. The frequency of additive effects ranged between 0 and 21.43%. Indifference was recorded in all combinations of antibiotics/PEO (ranged from 10.71 to 67.86% per antibiotic), and finally, antagonistic effects were recorded in six out the nine combinations of antibiotics/PEO and in ranges from 10.71% and up to 25% of the assays ([Figures 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}).

###### 

Mean values of fractional inhibitory concentration indexes (FICI) for piperitenone epoxide and antibiotics against 28 *Staphylococcus aureus* strains.

  **Strain**           **AMP**   **CRO**   **LVX**   **LZD**   **MEM**   **MIN**   **PEN**   **TGC**   **VAN**
  -------------------- --------- --------- --------- --------- --------- --------- --------- --------- ---------
  *S. aureus 1*        0.31      0.25      0.16      0.38      3.00      1.50      0.50      0.63      0.38
  *S. aureus 2*        0.56      0.63      0.51      0.56      2.50      0.63      0.56      2.00      0.75
  *S. aureus 3*        0.73      0.50      0.49      0.50      1.13      0.37      3.00      2.00      0.50
  *S. aureus 4*        0.38      0.50      0.12      0.50      0.49      0.49      0.31      2.00      1.50
  *S. aureus 5*        0.51      0.56      0.52      1.00      0.37      3.00      0.63      3.00      1.25
  *S. aureus 6*        0.38      0.50      0.27      0.38      0.25      0.37      0.50      2.00      0.50
  *S. aureus 7*        0.38      0.31      0.49      0.50      3.00      1.25      3.00      2.00      0.50
  *S. aureus 8*        1.25      0.38      1.13      0.50      0.37      1.13      1.25      2.00      0.63
  *S. aureus 9*        0.38      2.00      0.49      0.38      0.49      0.49      0.50      1.50      0.50
  *S. aureus 10*       0.51      0.75      0.51      0.75      1.13      0.49      2.50      2.00      0.75
  *S. aureus 11*       0.50      0.38      0.50      0.38      0.50      1.13      0.25      1.25      0.38
  *S. aureus 12*       0.26      0.38      0.37      0.38      1.48      0.50      0.38      3.08      0.38
  *S. aureus 13*       0.38      0.38      0.31      0.50      2.50      1.25      0.50      2.58      0.38
  *S. aureus 14*       0.56      1.50      0.31      0.63      1.48      0.56      2.50      2.00      0.75
  *S. aureus 15*       0.38      0.50      0.31      0.50      0.25      0.37      0.38      2.33      0.38
  *S. aureus 16*       0.38      0.38      0.25      0.38      1.25      0.63      0.38      2.00      0.38
  *S. aureus 17*       0.25      0.50      0.19      0.50      1.13      1.13      0.38      1.25      0.38
  *S. aureus 18*       3.00      0.56      1.02      1.25      3.00      1.25      4.50      2.00      0.75
  *S. aureus 19*       0.38      0.25      0.28      0.38      0.37      0.38      0.50      1.50      0.38
  *S. aureus 20*       3.00      0.38      0.51      0.63      1.24      1.50      0.75      2.00      0.75
  *S. aureus 21*       1.25      1.13      3.00      1.13      1.48      1.25      1.13      2.00      1.50
  *S. aureus 22*       0.38      0.31      0.50      0.38      0.31      1.25      0.50      1.50      0.38
  *S. aureus 23*       3.00      1.25      3.00      1.25      2.48      3.00      9.00      5.17      1.25
  *S. aureus 24*       1.13      1.25      3.00      1.13      1.13      2.25      2.13      2.00      2.00
  *S. aureus 25*       0.28      0.19      0.28      0.38      1.13      0.15      0.50      1.13      0.31
  *S. aureus 26*       1.13      0.38      0.25      0.38      5.00      0.38      1.13      0.63      0.38
  *S. aureus 27*       0.50      0.50      0.31      0.50      1.48      0.50      0.38      0.75      0.50
  *S. aureus 28*       0.38      0.50      0.31      0.38      0.31      0.50      0.50      0.49      0.50
  *S. aureus 25923*    0.28      0.25      0.16      0.38      0.25      0.37      0.50      0.63      0.38
  ^∗^Synergy(%)        57.14     67.86     67.86     67.86     35.71     42.86     53.57     3.57      60.71
  ^∗^Additive(%)       17.86     14.29     14.29     17.86     0         10.71     10.71     10.71     21.43
  ^∗^Indifference(%)   14.29     17.86     7.14      14.29     39.29     35.71     10.71     67.86     17.86
  ^∗^Antagonism (%)    10.71     0         10.71     0         25        10.71     25        17.86     0

∗

Reference strain not included. Ampicillin (AMP), Ceftriaxone (CRO), Levofloxacin (LVX), Linezolid (LZD), Meropenem (MEM), Minocycline (MIN), Penicillin (PEN), Tigecycline (TGC), Vancomycin (VAN).

![Percentages of synergy, additive, indifference, and antagonistic interactions between nine commercial antibiotics and piperitenone epoxide against clinical isolates of *Escherichia coli* from checkerboard assays.](fmicb-10-02607-g002){#F2}

![Percentages of synergy, additive, indifference, and antagonistic interactions between nine commercial antibiotics and piperitenone epoxide against clinical isolates of *Staphylococcus aureus* from checkerboard assays.](fmicb-10-02607-g003){#F3}

Discussion {#S4}
==========

Recent data suggest that the estimated burden of infection with antibiotic-resistant bacteria is substantial and has increased over the last years forcing toward comprehensive European and global action plans ([@B12]). Based on this increase in antibiotic resistance, products of natural origin as the EOs alone or in combination with other agents could be a promising alternative ([@B43]; [@B44]). EOs are secondary metabolites of aromatic and medicinal plants and play an important role in their proliferation and defense ([@B7]). Most of them are terpene and terpenoid mixtures with a lipophilic nature. However, since EOs are complex mixtures with variable and unsteady composition ([@B67]; [@B66]), they are hardly useful for medicinal use ([@B51]).

Piperitenone and piperitone are among the main components of various EOs isolated from aromatic and medicinal plants, particularly from *Mentha* sp., which, according to [@B47], belongs to piperitone/piperitenone type of EOs. From the limited available literature, it is known that both compounds have proven antimicrobial activities against *Mucor rouxii* ([@B6]), *S. aureus* ([@B47]), and *Aspergillus flavus* ([@B11]). Early studies have shown that PEO increased the antimicrobial activity of furazolidone and nitrofurantoin ([@B58]). Their mode of action is mostly associated with their lipophilic nature, the accumulation in membranes, and the sensitization of the phospholipidic bi-layer of the cell membrane causing an increase in permeability and leakage of various vital constituents ([@B15]; [@B48]). However, both epoxides have not been investigated for their synergism in combination with antibiotics.

The European Committee for Antimicrobial Susceptibility Testing (EUCAST) has proposed ([@B24]) a classification of the FICI occurring from a combination of antibiotics according to which any FICI ≤ 0.5 denotes synergy, additive when 0.5 \< FICI ≤ 1, indifference when 1 \< FICI \< 2, and antagonism when FICI ≥ 2. Another interpretation for checkerboard assays was proposed by [@B50], arguing about the reproducibility problems arising from the use of this methodology in comparison to others less prone to errors ([@B45]) but also less popular to microbiologists. According to [@B50], a synergy could be defined if FICI was ≤0.5 and antagonism when FICI \> 4. For FICI values between 0.5 and 4, "no interaction" should be stated. According to that author, such a conservative interpretation would be helpful for comparison purposes of the data published in the antimicrobial field. To deal with the reproducibility problems of the multiple checkerboard assays for the estimation of MIC and FIC, [@B27] proposed a modification in which both MIC and FIC are estimated in the same microplate. According to those authors, similar errors occur for the two estimations, and therefore, a synergistic effect is detected when FICI value \< 1, a cumulative effect when FICI value = 1, an indifferent effect when 1 \< FICI ≤ 2, and an antagonistic effect when FICI value \> 2 ([@B27]). In *E. coli* experiments which exhibited synergism, the mean reduction in the effective drug doses were 4-fold for amikacin, ceftazidime, minocycline and tigecycline, 8-fold for ampicillin and ceftriaxone, 16-fold for cefepime and meropenem, and up to 133-fold reduction for levofloxacin. The corresponding mean reductions for the drugs assayed in *S. aureus* strains were 8-fold for ampicillin, ceftriaxone, meropenem, and penicillin; 4-fold for linezolid, minocycline, tigecycline, and vancomycin; while there was a 66-fold mean reduction in the effective dose for levofloxacin. It is clear from our data that the use of PEO in combination with the various drugs gave some positive results about the synergistic effects, and despite the initial and relatively high MIC values of this compound, it finally reduced considerably the effective doses of the drugs even in the case of *E. coli* which, as a Gram(−) microorganism, is more resistant to the EOs antibacterial action ([@B43]).

The mechanism of action of PEO is not known, and this is also the case for any EO or their component. However, we can speculate on the site of action since there are relevant scientific evidence about molecules highly analogous to the PEO like carvacrol, thymol, and *p*-cymene. Among others, [@B71], [@B29], and [@B18] have studied the way carvacrol, a key compound in oregano EO, acts on the bacterial cell. They proposed that the membrane disruption and destabilization leading to leakage of cell ions, fluidization of membrane lipids, and the reduction in the proton motive force is the primary target for those molecules. Additional modes of action, following the disruption of the membrane with potential intracellular targets as the inhibition of ATPase activity, has been also proposed for thymol and *p*-cymene ([@B42]; [@B71]; [@B69]; [@B19]). In a similar way, we can speculate that the destabilization of the membrane by PEO results in a more efficient diffusion of drugs in the membrane or in the cell, thus exhibiting a higher activity being at a lower dose. However, in our study, decisive data like the minimum bactericidal concentration or time of kill were not estimated, and no molecular approaches were involved; therefore, no specific assumptions about the bactericidal effects can be drawn ([@B73]). Consequently, it is apparent that more research is needed to demonstrate the feasibility of use for the combined action of drugs and EOs constituents.

Conclusion {#S5}
==========

The multidrug-resistant microorganisms represent an increasingly widespread hazard. Essential oils could be an effective alternative to drugs in human and veterinary medicine. Particularly, various EOs compounds as the PEO, due to their promising synergistic or additive action, could be employed to reduce the effective drug dose against common pathogens, thus limiting the overuse of antibiotics or reducing their resistance.
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